3N9-64964-17785
2 vaccinations
1 coded response
1 check-in
1 free-text entry
0 call cases
- Sex
- Male
- Age at first dose
- 05-11
- ZIP prefix
- 852 / AZ
- Registered
- 2022-04-30
- Relationship
- Child or adolescent in my care
- Guardian
- 73W-32073-99552
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-01-20
Dose 1 — Pfizer-BioNTechCo-administered: Chickenpox:Rotavirus:Tetanus
-
2022-02-10
Dose 2 — Pfizer-BioNTech
-
2022-04-30
Registered in v-safe
-
2022-08-13
Survey response — 6 months, dose 2, dependentMedDRA: Cough, Pyrexia, Rhinorrhoea — Feeling: Good · Be unable to work or attend schoolFree text: High fever, runny nose, coughMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-01-20 | Pfizer-BioNTech | Chickenpox:Rotavirus:Tetanus |
| 2 | 2022-02-10 | Pfizer-BioNTech | No |
Free text
Release 12 — 6 months, dose 2, dependent
Symptoms: High fever, runny nose, cough
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release